Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 126.03 USD -1.28% Market Closed
Market Cap: 7.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Cost of Revenue Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
F
FLUO
BIOPOR

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Cost of Revenue
-€45.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Cost of Revenue
-kr601m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Cost of Revenue
-kr21.5m
CAGR 3-Years
19%
CAGR 5-Years
-120%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Cost of Revenue
-kr2.6B
CAGR 3-Years
-30%
CAGR 5-Years
-53%
CAGR 10-Years
-18%
F
Fluoguide AS
STO:FLUO
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Cost of Revenue
-kr9.8m
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
-3%

See Also

What is Ascendis Pharma A/S's Cost of Revenue?
Cost of Revenue
-45.9m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Cost of Revenue amounts to -45.9m EUR.

What is Ascendis Pharma A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-88%

Over the last year, the Cost of Revenue growth was -88%.

Back to Top